ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead candidate firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway on behalf of AVBP investors.
NEW YORK, Oct. 13, 2026 /PRNewswire/ -- A missed primary endpoint in the pivotal Phase 3 FURVENT trial of firmonertinib sent ArriVent BioPharma (NASDAQ: AVBP) shares down between 50% and 63% today, October 6, 2026, to a 52-week low near $12.09. If you held AVBP shares going into today's announcement, you may have legal rights. AVBP investors who suffered losses are encouraged to submit their loss information today. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
FURVENT is a global Phase 3 study of firmonertinib in previously untreated patients with EGFR exon 20 insertion-mutated non-small-cell lung cancer. Its primary endpoint was progression-free survival assessed by blinded independent central review. According to the Company's program update, FURVENT did not meet that endpoint. ArriVent reported some secondary-endpoint benefits and no new safety signals.
Firmonertinib is ArriVent's lead pipeline candidate, and the Company's SEC filings described FURVENT as a pivotal trial with topline data expected in 2026. Shares were down roughly 56.7% before the opening bell, and one report placed the intraday low at $11.88. Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of AVBP investors.
Lost money on AVBP? Start your AVBP loss review now or call (212) 363-7500.
WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.
Frequently Asked Questions About the AVBP Investigation
Q: Who is eligible to participate in the AVBP investigation?A: Investors who purchased AVBP stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: How much did AVBP stock drop?A: Shares fell approximately 50% to 63% on October 6, 2026, reaching a 52-week low near $12.09, after the Company disclosed that its Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: What do AVBP investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my AVBP shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought AVBP and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: What if I live outside the United States?A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
jlevi@levikorsinsky.com\
Tel: (212) 363-7500\
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/arrivent-biopharma-avbp-securities-investigation-notice---levi--korsinsky-302907413.html
SOURCE Levi & Korsinsky, LLP
